Opening an IND for an investigator-sponsored study of a Durasert implant for severe knee osteoarthritis. Good results from pre-clinical testing that have allowed us to identify a product candidate to treat wet age-related macular degeneration as an implant, delivering a tyrosine kinase inhibitor. We also have favorable Tethadur pre-clinical results, and a strengthened research and development program. So let’s move on to the details. no dataWe have continued to successfully move through the steps toward approval of Medidur for posterior segment uveitis, our lead development product. Following the very favorable top line results reported in the primary endpoints from our first Phase 3 clinical trial in six months, our 12-month follow-up reported consistent favorable results, specifically, at 12 months we maintained the same high level of statistical significance in preventing recurrence of disease that was achieved in meeting the primary efficacy endpoint at six months. This is very encouraging. Read More That, and just over a quarter of the Medidur-treated eyes had a recurrence of the disease through 12 months compared to about 85% of control eyes, is clearly very impressive. Safety data also remains favorable through the last follow-up visit, which ranged between 12 and 30 months. The incremental risk of elevated intraocular pressure, or IOP, in Medidur-treated eyes compared to control was small. The risk was actually lower through the last followup than it was through six months.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-psdv-earnings-conference-060317304.html
She has volunteered in eye clinics in the Dominican Republic and Bosnia. Laboratory studies are unlikely to be helpful in cases of mild, unilateral nongranulomatous uveitis in the following settings: History and physical not suggestive of systemic disease A non-specific work up is indicated if the history and the physical examination findings are unremarkable in the presence of uveitis that is bilateral, granulomatous, or recurrent. 2, 1 The following tests may be ordered by the consulting ophthalmologist, to be followed and further coordinated by the primary care physician: Complete blood cell BBC count Erythrocyte sedimentation rate ear Venereal disease research laboratory VDRL Purified protein derivative PDP DLA testing for ankylosing spondylarthroses Chest radiography to assess for sarcoidosis or tuberculosis Urinalysis for red blood cells or casts Infectious work up Ag, HIV, toxoplasmosis, depending on the presentation Uveitis has no standard treatment regimen. Am J Ophthalmol. 2006;1411:157-66. The urea pronounced “You-Vay-Uh” is a layer of the eye made up of three parts. Causes of uveitis in the general practice of ophthalmology. It almost always includes steroids taken by mouth. Untreated or under-treated uveitis, or repeated episodes of inflammation within the eye, can lead to scarring and blinding consequences. no dataDo I need to see other doctors?